Corporate Presentation

OTCQB: CTCO

This presentation contains certain forward-looking statements regarding the Company’s strategy and growth prospects as well as the drivers of the Company’s business which are subject to risks and uncertainties. The forward-looking statements in this presentation are subject to risks and uncertainties and include statements regarding our financial position, business strategy, and other plans and objectives for future operations, as well as any other statements which are not based on historical facts. Although we believe that these statements are based on reasonable assumptions, they are subject to numerous factors, risks, and uncertainties that could cause actual outcomes and result to be materially different from those projected. These factors, risks, and uncertainties include the Company’s limited operating history and inability to predict future operations with any certainty. Cannabis Therapy Corp. (OTCQB: CTCO) as well as any divisions, subsidiaries or affiliates does not undertake to update any forward-looking statements. This presentation does not constitute an offer to sell or the solicitation of an offer to buy securities of Cannabis Therapy Corp.

Legal

3

Mission Statement

“Our mission is to develop and market safe, cannabis based medicinal products by applying rigorous manufacturing and quality control standards, and to become a global leader in the research, development, manufacturing, testing and marketing of cannabis based therapies.”

--Soren Mogelsvang, CEO Cannabis Therapy Corp.

4

• Cannabis Therapy Corp. is a development stage company managed by a team of biotech entrepreneurs and executives.

• A focused strategy to develop, test and market safe, medicinal products based on hemp, a low-THC cannabis plant.

• Uniting world-class business, scientific, financial and technical expertise to leverage a unique opportunity in a rapidly expanding, undervalued and underdeveloped market.

• Unique approach using US grown hemp, a legal, low-THC cannabis variety as the basis for product development and manufacturing.

• Planned product development and manufacturing will use biopharma standards and quality control processes.

Company Overview

The Cannabis Revolution

"If Marijuana were unknown, it's discovery would no doubt be hailed as a medical breakthrough. Scientists would praise it's potential for treating everything from pain to cancer and marvel at it's rich pharmacopoeia…”

-- The Economist

“The science is there. This isn’t anecdotal…”

-- Dr. Sanjay Gupta

A modern day gold rush, with an estimated market size of $8.9 billion by 2016.

6

Opportunity and Market Growth

• For most of the past century, investment and research in medical cannabis was virtually non-existent due to legal restrictions.

• With the gradual legalization of medical cannabis and industrial hemp at the state level, research into medical, pharmaceutical and industrial applications is expanding dramatically.

• The medical marijuana market is projected to reach $8.9 billion by 2016

• The global nutraceuticals market is projected to reach $207 billion by 2016.

“Cannabis has been used medicinally for thousands of years to relieve symptoms of pain, nausea, anorexia, muscle stiffness, bladder dysfunction, and to treat a range of sleep, pain and physiological disorders.”

Nutraceutical Sector

• Nutritional supplements or ‘functional foods’ that promise medical or health benefits.• Products range from isolated nutrients, dietary supplements and herbal remedies, to

specific diets, certain processed foods and beverages.• Extremely attractive to food and beverage companies due to comparatively high

margins.

8

• Hemp is a cannabis variety with minimal or no THC. Certain hemp strains naturally retain medicinally active cannabinoid components. Most importantly, the plant can be grown and processed legally in the US under existing laws.

• CTC is focused on developing non-psychoactive (“no-high”) medicinal products based on US grown hemp, allowing safe treatment with no side-effects.

• CTC is developing proprietary extraction methods for the production of pure and safe medicinal compounds, known as cannabinoids and terpenes, with a specific focus on developing products for inflammatory and auto-immune diseases.

• CTC is establishing collaborations with leading plant breeders to develop improved and proprietary hemp strains.

• CTC’s strategy is to employ rigorous biopharma processes and quality controls to manufacture safe, hemp-based products and to target the nutraceutical market which offers a short path to commercialization.

Cannabis Snapshot

• The Cannabis plant has medicinal properties, similar to conventional prescription drugs, and has been used to treat ailments and diseases throughout history.

9

Phytocannabinoids are the naturally occurring therapeutic components of cannabis plants (cannabis sativa)

-- these are not synthetic products• Grown in almost any climate, including indoors, over 2000

cannabis strains with differing properties exist.• Phytocannabinoids are made exclusively by the cannabis plant

and have well-documented therapeutic potential.• CBD (Cannabidiol) is an abundant and therapeutically active

phytocannabinoid from the cannabis plant.• CTC aims to harness the medicinal potential of the

phytocannabinoids and terpenes made by low-THC hemp plants, to develop safe, nutraceutical products for treatment of inflammatory and auto-immune diseases.

Natural Components

• Cannabinoids have proven effective in the treatment of a wide variety of diseases and are ideally suited for rapid commercialization.

• CTC’s value proposition is to develop and commercialize safe, hemp-based products for the prevention and treatment of inflammatory and auto-immune diseases.

Therapeutic Context

11

• Focus on unique and proprietary hemp strains offering elevated cannabinoid content and superior therapeutic potential, thereby eliminating the regulatory constraints associated with traditional medical marijuana.

• Employ biopharmaceutical cannabinoid extraction and characterization processes to manufacture safe, consistent, high-quality hemp-based nutraceutical products.

• Partner with universities and research institutions to develop improved and proprietary technology and processes.

• Work with clinicians to test advanced, hemp-based products for treatment of inflammatory and auto-immune diseases.

Business Strategy

From cultivation to research, manufacturing to consumer sales, Cannabis Therapy Corp. will earn revenue from the development and marketing of hemp-based products for treatment of inflammatory and auto-immune diseases.

Integrated Operations

13

Business Development - Timeline

2014-2015

Solidify a vertically integrated enterprise• Sourcing & development of medicinal hemp strains.• Controlled growth and testing of selected strains. • Establish standard operating procedures (SOPs) for terpene and

cannabinoid extraction, processing and testing.• Build IP position for processes, formulations & technology.• Establish product pipeline, with 1-2 lead products.• Build marketing channels to distributors, partners and patients.• Initiate domestic sales in 2015, with future expansion to

international markets.• Develop strategic alliances and partnerships within the industry.

14

Cannabinoids have almost infinite potential for treatment of a wide range of human conditions and diseases

* Any single product could become a blockbuster by itself… …if approved by the FDA… which requires time, research, trials and significant investment.

* CTC will target the over-the-counter, nutraceutical (supplement) market thereby eliminating the lengthy and expensive FDA approval process.

• Rapid penetration of the nutraceutical (supplement) market is targeted through provision of safe, high-quality products, backed by strong research and quality control.

• The US nutritional market is >$30 billion and single products can become blockbusters (e.g. fish-oil extracts, omega 3); cannabinoid-based products could generate well over $1 billion annually before 2019, with CTC contributing >20%.

Shortened Time-to-Market

“Management is, above all, a practice where art, science, and craft meet”― Henry Mintzberg

Dr. Soren Mogelsvang, President and CEOA biotech executive and entrepreneur with over 15 years of experience in translational research, drug discovery and ISO compliant manufacturing, Dr. Mogelsvang brings to CTC a proven track record in product and IP development, laboratory and operations management. He has a track record of building highly efficient and productive laboratories around the globe; and holds a PhD in Biochemistry (Cambridge, UK), and an MSc in plant molecular biology (University of Copenhagen).

Mr. Arnold Tinter, CFOAn experience executive who has served as CFO and CEO of multiple public companies over the past 45 years. Mr. Tinter received a B.S. degree in Accounting in 1967 from C.W. Post College, Long Island University, and is licensed as a Certified Public Accountant in Colorado.

Management

Mr. Guy Yachin, DirectorCurrently the CEO of Serpin Pharma Inc., a privately held, development stage biotech company in Virginia, USA, Mr. Yachin is a serial entrepreneur who has led as CEO of numerous biomedical companies. Mr. Yachin has sat on the board of multiple companies including Orgenesis, Remon Medical Technologies, Enzymotec and NanoPass. He holds a BSc. and an MBA from Technion – Israel Institute of Technology.Dr. Cohava Gelber, DirectorAn executive with over 25 years of experience in discovery and development of immune therapeutics and diagnostics for cancer, autoimmune disease, allergies and infectious diseases, Dr. Gelber has held various executive positions in academia (Duke University) and biopharmaceutical companies (ImmuLogic Pharmaceutical Corporation, Molecular Discoveries and MannKind Corporation). She holds a Ph.D. from the Weizmann Institute, an MBA from Cornell University and completed postdoctoral training at Stanford University. Ms. Vered Caplan, DirectorCurrently the CEO of Orgenesis, Inc., a development stage company offering therapeutic technology as a treatment for diabetes. Ms. Caplan was previously Chief Executive Officer of Kamedis, a company focused on utilizing plant extracts for dermatology purposes. From 2004 to 2007, Ms. Caplan was Chief Executive Officer of GammaCan, a company focused on the use of immunoglobulins for the treatment of cancer. Ms. Caplan has a M.Sc. in bio-medical engineering from Tel-Aviv University; and a B.Sc. in mechanical engineering from the Technion Institute of Technology.

Management – cont’d

17

• Create new intellectual property and proprietary assets by leveraging its extensive experience in biotech and drug development.

• Reach profitability within 24 months, gain 2% market penetration, with sales exceeding $200 million by 2018

• Achieve the goal of providing optimal returns for our shareholders.

Summary

Cannabis Therapy Corp (OTCQB: CTCO) aims to: • Become the leading provider of safe, superior quality, hemp-based products for

treatment of inflammatory and auto-immune diseases.• Rapidly integrate it’s products into the fast-growing, high-return nutraceutical

market.• Establish strategic partnerships and collaborations to achieve long-term success in

the exploding medical cannabis and nutraceutical sectors. • Generate earnings through multiple synergistic revenue streams derived from

proprietary products and laboratory services.

18

Profile

Cannabis Therapy Corp.4450 Arapahoe Ave, Suite 100Boulder, CO 80303

Investor Relations:T: +1 (800) 713-9091E: investors@cannabistherapy.com

OTCQB: CTCOCUSIP: 13764J 107State of Incorporation: NVSEC Reporting Status: CompliantDate of Incorporation: Dec. 18, 2007Fiscal Year End: Sept. 30Shares Issued and Outstanding: 70,312,998 on March 31, 2014

Legal CounselCrone Kline Rinde LLP

488 Madison Avenue, 12th FloorNew York, NY 10022

Transfer Agent: Securities Transfer Corporation2591 Dallas Parkway, Suite 102

Frisco, TX 75034Phone: 469.633.0101www.stctransfer.com

Auditors: MaloneBailey, LLP

9801 Westheimer RoadHouston, TX 77042

OTCQB: CTCO

www.cannabistherapy.com